AR030179A1 - Combinaciones de un inhibidor de tirosinquinasa de receptores abl, de pdgf y de kit con un compuesto organico capaz de enlazarse con glicoproteina acido-alfa1, un producto, el uso de dicha combinacion para producir un producto farmaceutico y un producto farmaceutico - Google Patents
Combinaciones de un inhibidor de tirosinquinasa de receptores abl, de pdgf y de kit con un compuesto organico capaz de enlazarse con glicoproteina acido-alfa1, un producto, el uso de dicha combinacion para producir un producto farmaceutico y un producto farmaceuticoInfo
- Publication number
- AR030179A1 AR030179A1 ARP000106887A ARP000106887A AR030179A1 AR 030179 A1 AR030179 A1 AR 030179A1 AR P000106887 A ARP000106887 A AR P000106887A AR P000106887 A ARP000106887 A AR P000106887A AR 030179 A1 AR030179 A1 AR 030179A1
- Authority
- AR
- Argentina
- Prior art keywords
- receptor
- abl
- pdgf
- product
- kit
- Prior art date
Links
- 239000002131 composite material Substances 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 108020003175 receptors Proteins 0.000 abstract 8
- 102000005962 receptors Human genes 0.000 abstract 8
- 108091008606 PDGF receptors Proteins 0.000 abstract 4
- 102000011653 Platelet-Derived Growth Factor Receptors Human genes 0.000 abstract 3
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 abstract 2
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 230000005764 inhibitory process Effects 0.000 abstract 2
- 150000002894 organic compounds Chemical class 0.000 abstract 2
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 2
- 229940127557 pharmaceutical product Drugs 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 abstract 2
- 239000005483 tyrosine kinase inhibitor Substances 0.000 abstract 2
- 150000004917 tyrosine kinase inhibitor derivatives Chemical class 0.000 abstract 2
- 102000003886 Glycoproteins Human genes 0.000 abstract 1
- 108090000288 Glycoproteins Proteins 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000002062 proliferating effect Effects 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Dermatology (AREA)
- Oncology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Saccharide Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT1999MI002711A ITMI992711A1 (it) | 1999-12-27 | 1999-12-27 | Composti organici |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR030179A1 true AR030179A1 (es) | 2003-08-13 |
Family
ID=11384195
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP000106887A AR030179A1 (es) | 1999-12-27 | 2000-12-22 | Combinaciones de un inhibidor de tirosinquinasa de receptores abl, de pdgf y de kit con un compuesto organico capaz de enlazarse con glicoproteina acido-alfa1, un producto, el uso de dicha combinacion para producir un producto farmaceutico y un producto farmaceutico |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US20030125343A1 (enExample) |
| EP (1) | EP1250140B1 (enExample) |
| JP (1) | JP2003523325A (enExample) |
| CN (1) | CN1304005C (enExample) |
| AR (1) | AR030179A1 (enExample) |
| AT (1) | ATE432069T1 (enExample) |
| AU (1) | AU2171901A (enExample) |
| BR (1) | BR0016817A (enExample) |
| CA (1) | CA2394944A1 (enExample) |
| CO (1) | CO5271710A1 (enExample) |
| DE (1) | DE60042283D1 (enExample) |
| ES (1) | ES2326307T3 (enExample) |
| HK (1) | HK1050993A1 (enExample) |
| IT (1) | ITMI992711A1 (enExample) |
| PE (1) | PE20010991A1 (enExample) |
| PT (1) | PT1250140E (enExample) |
| TW (1) | TWI246917B (enExample) |
| WO (1) | WO2001047507A2 (enExample) |
Families Citing this family (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040034026A1 (en) * | 2000-11-22 | 2004-02-19 | Wood Jeannette M | Combination comprising an agent decreasing vegf activity and an agent decreasing egf activity |
| WO2003000186A2 (en) | 2001-06-21 | 2003-01-03 | Ariad Pharmaceuticals, Inc. | Novel phenylamino-pyrimidines and uses thereof |
| US7323469B2 (en) | 2001-08-07 | 2008-01-29 | Novartis Ag | 7H-pyrrolo[2,3-d]pyrimidine derivatives |
| GB0119249D0 (en) | 2001-08-07 | 2001-10-03 | Novartis Ag | Organic compounds |
| DE10141650C1 (de) | 2001-08-24 | 2002-11-28 | Lohmann Therapie Syst Lts | Transdermales Therapeutisches System mit Fentanyl bzw. verwandten Substanzen |
| DE60224299T2 (de) * | 2001-10-25 | 2008-12-11 | Novartis Ag | Kombinationsmedikationen mit einem selektiven cyclooxygenase-2-inhibitor |
| GB0201508D0 (en) | 2002-01-23 | 2002-03-13 | Novartis Ag | Organic compounds |
| CA2479257A1 (en) * | 2002-03-21 | 2003-10-02 | Dana-Farber Cancer Institute, Inc. | Inhibition of cell death responses induced by oxidative stress |
| AU2007201830C1 (en) * | 2002-04-23 | 2017-09-07 | Novartis Pharma Ag | High drug load tablet |
| GB0209265D0 (en) | 2002-04-23 | 2002-06-05 | Novartis Ag | Organic compounds |
| US20060052387A1 (en) * | 2002-06-26 | 2006-03-09 | Marsh Clay B | Organic compounds |
| CA2498982A1 (en) * | 2002-07-24 | 2004-01-29 | Novartis Ag | 4-(4-methylpiperazin-1-ylmethyl)-n-[4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide for treating anaplastic thyroid cancer |
| EP1542989B1 (en) * | 2002-07-31 | 2007-04-18 | Critical Outcome Technologies, Inc. | Protein tyrosine kinase inhibitors |
| GB0222514D0 (en) | 2002-09-27 | 2002-11-06 | Novartis Ag | Organic compounds |
| EP1551824B1 (en) * | 2002-10-09 | 2007-12-12 | Critical Outcome Technologies, Inc. | Protein tyrosine kinase inhibitors |
| JP2007523827A (ja) | 2003-08-25 | 2007-08-23 | ダナ−ファーバー キャンサー インスティテュート，インコーポレイテッド | 混合性白血病遺伝子の再構成を伴う急性リンパ芽球性白血病の処置方法 |
| MXPA06003056A (es) * | 2003-09-19 | 2006-05-31 | Novartis Ag | Tratamiento de tumores estromales gastrointestinales con imatinib y midostaurin. |
| TW200517114A (en) * | 2003-10-15 | 2005-06-01 | Combinatorx Inc | Methods and reagents for the treatment of immunoinflammatory disorders |
| WO2005077933A1 (en) † | 2004-02-11 | 2005-08-25 | Natco Pharma Limited | Novel polymorphic form of imatinib mesylate and a process for its preparation |
| US7358250B2 (en) | 2004-06-29 | 2008-04-15 | Amgen Inc. | Pyrrolo[2,3-d]pyrimidines that modulate ACK1 activity |
| MX2007001399A (es) * | 2004-08-02 | 2007-04-18 | Osi Pharm Inc | Compuestos que inhiben pirrolopirimidina multi-cinasa aril-amino sustituidas. |
| JP5208516B2 (ja) | 2004-12-30 | 2013-06-12 | エグゼリクシス， インコーポレイテッド | キナーゼモジュレーターとしてのピリミジン誘導体および使用方法 |
| US20070059359A1 (en) * | 2005-06-07 | 2007-03-15 | Thomas Backensfeld | Immediate-release and high-drug-load pharmaceutical formulations of non-micronised (4-chlorophenyl)[4-(4-pyridylmethyl)phthalazin-1-yl] and salts thereof |
| US20060275365A1 (en) * | 2005-06-07 | 2006-12-07 | Thomas Backensfeld | Immediate-release and high-drug-load pharmaceutical formulations of micronised (4-chlorophenyl) [4-(4-pyridylmethyl)phthalazin-1-yl] and salts thereof |
| WO2006136391A2 (en) * | 2005-06-23 | 2006-12-28 | Novartis Ag | Treatment of solid tumor disease with combinations comprising imatinib and an efflux pump inhibitor |
| US7910595B2 (en) * | 2005-12-21 | 2011-03-22 | Abbott Laboratories | Anti-viral compounds |
| ES2395386T3 (es) | 2005-12-21 | 2013-02-12 | Abbott Laboratories | Compuestos antivirales |
| ATE475660T1 (de) | 2005-12-21 | 2010-08-15 | Abbott Lab | Antivirale verbindungen |
| SG171592A1 (en) * | 2006-04-20 | 2011-06-29 | Janssen Pharmaceutica Nv | Method of inhibiting c-kit kinase |
| US8222256B2 (en) | 2006-07-05 | 2012-07-17 | Exelixis, Inc. | Methods of using IGFIR and ABL kinase modulators |
| TWI399380B (zh) | 2006-12-20 | 2013-06-21 | Abbott Lab | 抗病毒化合物 |
| CA2673683C (en) | 2007-01-11 | 2014-07-29 | Critical Outcome Technologies, Inc. | Compounds and method for treatment of cancer |
| US8138191B2 (en) | 2007-01-11 | 2012-03-20 | Critical Outcome Technologies Inc. | Inhibitor compounds and cancer treatment methods |
| US20080248548A1 (en) * | 2007-04-09 | 2008-10-09 | Flynn Daniel L | Modulation of protein functionalities |
| US8414918B2 (en) * | 2007-09-25 | 2013-04-09 | Teva Pharmaceutical Industries Ltd. | Stable imatinib compositions |
| WO2009079797A1 (en) | 2007-12-26 | 2009-07-02 | Critical Outcome Technologies, Inc. | Compounds and method for treatment of cancer |
| AP2010005347A0 (en) | 2008-01-11 | 2010-08-31 | Natco Pharma Ltd | Novel pyrazolo [3,4-D] pyrimidine derivatives as anti-cancer agents |
| US9273077B2 (en) | 2008-05-21 | 2016-03-01 | Ariad Pharmaceuticals, Inc. | Phosphorus derivatives as kinase inhibitors |
| AU2009248923B2 (en) | 2008-05-21 | 2015-01-29 | Takeda Pharmaceutical Company Limited | Phosphorous derivatives as kinase inhibitors |
| CA2744563A1 (en) | 2008-12-12 | 2010-06-17 | Ariad Pharmaceuticals, Inc. | Azaindole derivatives as kinase inhibitors |
| ITRM20090578A1 (it) * | 2009-11-10 | 2011-05-11 | Noi Per Voi Onlus | Nuove composizioni per il trattamento di leucemie chemioresistenti e/o di leucemie potenzialmente chemioresistenti. |
| CA2794952C (en) | 2010-04-01 | 2018-05-15 | Critical Outcome Technologies Inc. | Compounds and method for treatment of hiv |
| US20120115878A1 (en) | 2010-11-10 | 2012-05-10 | John Vincent Calienni | Salt(s) of 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7h-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide and processes of making thereof |
| TR201010618A2 (tr) * | 2010-12-20 | 2012-07-23 | Bi̇lgi̇ç Mahmut | İmatinib içeren bir oral dozaj formu ve bu oral dozaj formunun üretimi |
| PL394169A1 (pl) | 2011-03-09 | 2012-09-10 | Adamed Spółka Z Ograniczoną Odpowiedzialnością | Kompozycja farmaceutyczna metanosulfonianu imatinibu do napełniania jednostkowych postaci dawkowania oraz sposób jej wytwarzania |
| US9834518B2 (en) | 2011-05-04 | 2017-12-05 | Ariad Pharmaceuticals, Inc. | Compounds for inhibiting cell proliferation in EGFR-driven cancers |
| US20160015708A1 (en) | 2012-02-21 | 2016-01-21 | Ranbaxy Laboratories Limited | Stable dosage forms of imatinib mesylate |
| JP6469567B2 (ja) | 2012-05-05 | 2019-02-13 | アリアド・ファーマシューティカルズ・インコーポレイテッド | Ｅｇｆｒ発動性がんの細胞増殖阻害用化合物 |
| US9611283B1 (en) | 2013-04-10 | 2017-04-04 | Ariad Pharmaceuticals, Inc. | Methods for inhibiting cell proliferation in ALK-driven cancers |
| WO2017078647A1 (en) | 2015-11-05 | 2017-05-11 | Koçak Farma Ilaç Ve Kimya Sanayi Anonim Şirketi | Pharmaceutical compositions of imatinib |
| EP3257499A1 (en) | 2016-06-17 | 2017-12-20 | Vipharm S.A. | Process for preparation of imatinib methanesulfonate capsules |
| IL284510B2 (en) | 2019-01-23 | 2025-10-01 | Novartis Ag | Crystalline forms of succinate salt of 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-h7-pyrrolo[3,2-d]pyrimidine-6-carboxylic acid dimethylamide |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5587459A (en) * | 1994-08-19 | 1996-12-24 | Regents Of The University Of Minnesota | Immunoconjugates comprising tyrosine kinase inhibitors |
| US5750493A (en) * | 1995-08-30 | 1998-05-12 | Raymond F. Schinazi | Method to improve the biological and antiviral activity of protease inhibitors |
| US20030069174A1 (en) * | 1997-03-10 | 2003-04-10 | Ludwig Pichler | Use of human alpha1-acid glycoprotein for producing a pharmaceutical preparation |
| CO4940418A1 (es) * | 1997-07-18 | 2000-07-24 | Novartis Ag | Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso |
| US6806266B1 (en) * | 1999-07-13 | 2004-10-19 | Kyowa Hakko Kogyo Co., Ltd. | Staurosporin derivatives |
| CN1195755C (zh) * | 1999-12-10 | 2005-04-06 | 辉瑞产品公司 | 吡咯并[2,3－d]嘧啶化合物 |
-
1999
- 1999-12-27 IT IT1999MI002711A patent/ITMI992711A1/it unknown
-
2000
- 2000-12-08 TW TW089126229A patent/TWI246917B/zh active
- 2000-12-22 EP EP00985244A patent/EP1250140B1/en not_active Expired - Lifetime
- 2000-12-22 AU AU21719/01A patent/AU2171901A/en not_active Abandoned
- 2000-12-22 WO PCT/EP2000/013161 patent/WO2001047507A2/en not_active Ceased
- 2000-12-22 HK HK03101801.4A patent/HK1050993A1/zh unknown
- 2000-12-22 AT AT00985244T patent/ATE432069T1/de active
- 2000-12-22 US US10/169,035 patent/US20030125343A1/en not_active Abandoned
- 2000-12-22 PE PE2000001393A patent/PE20010991A1/es not_active Application Discontinuation
- 2000-12-22 DE DE60042283T patent/DE60042283D1/de not_active Expired - Lifetime
- 2000-12-22 CA CA002394944A patent/CA2394944A1/en not_active Abandoned
- 2000-12-22 PT PT00985244T patent/PT1250140E/pt unknown
- 2000-12-22 BR BR0016817-3A patent/BR0016817A/pt not_active Application Discontinuation
- 2000-12-22 CN CNB008178976A patent/CN1304005C/zh not_active Expired - Fee Related
- 2000-12-22 AR ARP000106887A patent/AR030179A1/es not_active Application Discontinuation
- 2000-12-22 CO CO00097404A patent/CO5271710A1/es not_active Application Discontinuation
- 2000-12-22 ES ES00985244T patent/ES2326307T3/es not_active Expired - Lifetime
- 2000-12-22 JP JP2001548102A patent/JP2003523325A/ja active Pending
-
2009
- 2009-03-04 US US12/397,374 patent/US20090221519A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| BR0016817A (pt) | 2002-10-01 |
| AU2171901A (en) | 2001-07-09 |
| ATE432069T1 (de) | 2009-06-15 |
| TWI246917B (en) | 2006-01-11 |
| EP1250140B1 (en) | 2009-05-27 |
| ITMI992711A0 (it) | 1999-12-27 |
| EP1250140A2 (en) | 2002-10-23 |
| DE60042283D1 (de) | 2009-07-09 |
| HK1050993A1 (zh) | 2003-07-18 |
| US20030125343A1 (en) | 2003-07-03 |
| ITMI992711A1 (it) | 2001-06-27 |
| PT1250140E (pt) | 2009-08-24 |
| CN1304005C (zh) | 2007-03-14 |
| US20090221519A1 (en) | 2009-09-03 |
| CN1414858A (zh) | 2003-04-30 |
| WO2001047507A3 (en) | 2002-04-04 |
| JP2003523325A (ja) | 2003-08-05 |
| CA2394944A1 (en) | 2001-07-05 |
| CO5271710A1 (es) | 2003-04-30 |
| ES2326307T3 (es) | 2009-10-07 |
| WO2001047507A2 (en) | 2001-07-05 |
| PE20010991A1 (es) | 2001-10-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR030179A1 (es) | Combinaciones de un inhibidor de tirosinquinasa de receptores abl, de pdgf y de kit con un compuesto organico capaz de enlazarse con glicoproteina acido-alfa1, un producto, el uso de dicha combinacion para producir un producto farmaceutico y un producto farmaceutico | |
| AR048502A1 (es) | Sinergia terapeutica de compuestos anti-cancer | |
| CR8181A (es) | Uso de una combinacion de un inhibidor de la cinasa del receptor del factor de crecimiento epidermico y agentes citotoxicos para el tratamiento e inhibicion del cancer | |
| CO6331425A2 (es) | Composiciones que comprenden n-(3,4-difluoro-2-(2-fluoro-4-yodofenilamino)6-metoxifenil)-1-(2,3-dihidroxiproxipropil)ciclopropan-1-sulfamida | |
| BRPI0612845A8 (pt) | composto, formulação farmacêutica, métodos para tratar câncer e para sintetizar um composto de fórmula alq-dispasador | |
| GEP20115283B (en) | Pyrrolopyrimidine compounds and their uses | |
| ECSP056194A (es) | Derivados de pirazolo-quinazolina, procedimiento para su preparacion y su uso como inhibidores de quinasa | |
| CL2009000241A1 (es) | Compuestos derivados de 5-(2-morfolin-4-il-7h-pirrolo[2,3-d]pirimidin-4-il)pirimidin-2-ilamina; proceso de preparacion; composicion farmaceutica; y uso de los compuestos para tratar o prevenir una enfermedad proliferativa tal como el cancer. | |
| CY1112478T1 (el) | Ενωσεις κιναζολινονης ως αντικαρκινικοι παραγοντες | |
| BRPI0606996A2 (pt) | combinação de compostos orgánicos, uso da mesma e composição farmacêutica | |
| RU2018146886A (ru) | Пути терапевтического применения ингибитора c-raf | |
| AR047988A1 (es) | Combinaciones antineoplásicas de cci-779 y rituximab | |
| AR044039A1 (es) | Combinaciones antineoplasicas | |
| AR074778A1 (es) | Composicion farmaceutica, con anticuerpo monoclonal humano anti - igf-ir. | |
| WO2003063787A3 (en) | Non-steroidal analogs of 2-methoxyestradiol | |
| CU20090007A6 (es) | Un compuesto farmacéutico y un proceso del mismo | |
| CR20190429A (es) | COMPUESTOS DE TIPO IMIDAZO[4,5-c]QUINOLIN-2-ONA-DEUTERADOS Y SU USO EN EL TRATAMIENTO DEL CÁNCER | |
| PL342614A1 (en) | Anticarcinogenic drugs | |
| WO2022061155A9 (en) | Imidazopyridazine and imidazopyrazine compounds as inhibitors of cdk7 | |
| ES2582660T3 (es) | Sidnoniminas - inhibidores específicos de la recaptación de la dopamina y su uso en el tratamiento de los trastornos relacionados con la dopamina | |
| BRPI0507482A (pt) | combinação de (a) um inibidor de dna topoisomerase e (b) um inibidor de iap | |
| AR036321A1 (es) | Metodo y formulacion farmaceutica para el tratamiento de la discinesia de aparicion tardia. | |
| BR0112122A (pt) | Composto de rutênio (ii) , uso de um composto, composição farmacêutica, método para tratar e/ou prevenir o câncer, e, processo para preparar um composto | |
| AR049135A1 (es) | Composicion,metodo, kit y tratamiento con oxaliplatino y un inhibidor del egfr,como erlotinib | |
| BRPI0514187A (pt) | composto, e, droga preventiva ou uma droga terapêutica |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |